HBsAg 소실 후 경구 핵산유사체를 중단한 만성 B형간염의 혈청 재양전 및 급성 악화 = Seroreversion and Acute Decompensation in Chronic Hepatitis B after Discontinuation of Oral Nucleotide Analog in the Patients Achieving HBsAg Loss

다국어 초록 (Multilingual Abstract)

Although rare patients with chronic hepatitis B can achieve HBsAg loss on oral nucleos(t)ide analog (NA), the optimal timing of stopping oral NAs safely has been considered when HBsAg and HBV DNA are negative in the serum because HBsAg loss induced by nucleos(t)ide analogs (NAs) appears to be durable if immunosuppressive therapy or chemotherapy are not done. On the other hand, the author experienced a case of HBsAg seroreversion and acute decompensation after the discontinuation of NA in a patient with HBsAg loss. This rare case highlights the need for the close monitoring of patients who achieved HBsAg loss and stopped NA. (Korean J Gastroenterol 2020;76:256-260)

참고문헌 (Reference)

1 Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018hepatitis B guidance" 67 : 1560-1599, 2018

2 Cornberg M, "The role of quantitative hepatitis B surface antigen revisited" 66 : 398-411, 2017

3 Liu F, "Systematic review with meta-analysis : development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance" 43 : 1253-1261, 2016

4 Testoni B, "Serum hepatitis B core-related antigen(HBcrAg)correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients" 70 : 615-625, 2019

5 Zoulim F, "New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA" 42 : 302-308, 2005

6 Hu HH, "Level of hepatitis B(HB)core antibody associates with seroclearance of HBV DNA and HB surface antigen in HB e antigen-seronegative patients" 17 : 172-181.e1, 2019

7 Cornberg M, "HBsAg seroclearance with NUCs : rare but important" 63 : 1208-1209, 2014

8 Kim GA, "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B : clinical outcomes and durability" 63 : 1325-1332, 2014

9 Martinot-Peignoux M, "HBsAg quantification : useful for monitoring natural history and treatment outcome" 34 (34): 97-107, 2014

10 Cornberg M, "Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference" 72 : 539-557, 2020

11 Calvaruso V, "Fibrosis in chronic viral hepatitis" 25 : 219-230, 2011

12 European Association For The Study Of The Liver, "EASL clinical practice guidelines : management of chronic hepatitis B virus infection" 57 : 167-185, 2012

13 European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection" 67 : 370-398, 2017

14 Yip TC, "Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients" 68 : 63-72, 2018

15 Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B" 63 : 261-283, 2016